Applied DNA Sciences (APDN) Misses Q4 EPS by 1c
Applied DNA Sciences (NASDAQ: APDN) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $1.79 million.
Excluding non-cash expenses, Adjusted EBITDA for the quarter ended September 30, 2016 was negative $1.7 million compared to a positive Adjusted EBITDA of $213 thousand for the same quarter last year and a negative Adjusted EBITDA of $2.6 million in the prior fiscal quarter.
For earnings history and earnings-related data on Applied DNA Sciences (APDN) click here.